Bioprocessing Technology Market Report 2026

The bioprocessing technology market size has grown rapidly in recent years. It will grow from $71.39 billion in 2025 to $81.45 billion in 2026 at a compound annual growth rate (CAGR) of 14.1%. The growth in the historic period can be attributed to growing demand for biologics production, expansion of biopharmaceutical manufacturing capacity, increasing adoption of cell culture technologies, rising investment in life sciences research, improved availability of bioprocessing consumables.

The bioprocessing technology market size is expected to see rapid growth in the next few years. It will grow to $139.77 billion in 2030 at a compound annual growth rate (CAGR) of 14.5%. The growth in the forecast period can be attributed to increasing demand for biosimilars and recombinant proteins, rising adoption of automation in biomanufacturing, expansion of personalized medicine production, growing focus on process optimization, increasing outsourcing to CMOs. Major trends in the forecast period include increasing adoption of single-use bioprocessing systems, rising use of automated cell expansion platforms, growing integration of advanced biologics safety testing, expansion of continuous bioprocessing techniques, enhanced focus on scalable biomanufacturing.

The rising incidence of chronic diseases is anticipated to significantly boost the growth of the bioprocessing technology market in the future. Chronic diseases are long-term health conditions that last for at least a year and can impair daily activities, necessitating ongoing medical care. Bioprocessing technologies are crucial for developing therapeutic proteins, polysaccharides, vaccines, and diagnostics essential for treating chronic diseases. Consequently, the growing prevalence of these diseases will drive the expansion of the bioprocessing technology market. For example, the World Health Organization, a United Nations agency based in Switzerland, projected in February 2024 that over 35 million new cancer cases will emerge by 2050, representing a 77% increase from the estimated 20 million cases in 2022. Thus, the rising incidence of chronic diseases is expected to propel the growth of the bioprocessing technology market.

Major entities in the bioprocessing technology domain are dedicated to developing comprehensive bioprocessing solutions, such as bioprocessing platforms, to meet the increasing demand for enhanced yields and maximize profitability. Bioprocessing platforms encompass technologies and methods tailored for efficient large-scale biological material processing, especially in producing biopharmaceuticals. For instance, WuXi Biologics introduced WuXiUI in October 2023, a high-productivity bioprocessing platform enhancing mammalian cell line productivity and product quality. Utilizing an ultra-intensified intermittent-perfusion fed-batch strategy, WuXiUI achieves 3 to 6-fold productivity increases compared to conventional processes, catering to the need for yield enhancement, cost reduction, and adherence to environmental, social, and governance (ESG) considerations in bioprocess development.

In August 2024, Merck KGaA, a science and technology company based in Germany, acquired Mirus Bio for $600 million. This acquisition is intended to strengthen Merck KGaA's viral vector bioprocessing capabilities, allowing the company to offer integrated solutions across the entire manufacturing spectrum, from preclinical stages to commercial production. Mirus Bio, a biotechnology company located in the U.S., specializes in delivering innovative solutions for life sciences research and gene delivery applications.

Major companies operating in the bioprocessing technology market report are Thermo Fisher Scientific Inc., Sartorius AG, Merck KGaA, Danaher Corporation, Lonza Group AG, GE Healthcare, Waters Corporation, STADA Arzneimittel AG, Bio-Rad Laboratories Inc., Applikon Biotechnology B.V., Agilent Technologies Inc., Solida Biotech GmbH, Fujifilm Healthcare Corporation, Catalent Inc., Asahi Kasei Medical Inc., Amgen Inc., Eppendorf AG, Repligen Corporation, Becton Dickinson and Company, MilliporeSigma, Novasep, Boehringer Ingelheim GmbH, Cytiva AB, Wuxi Biologics, AGC Biologics, Samsung Biologics, AbbVie Inc., Bristol Myers Squibb Company, Pfizer Inc., Roche Holding AG

North America was the largest region in the bioprocessing technology market in 2025. The regions covered in the bioprocessing technology market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the bioprocessing technology market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The bioprocess technology market includes revenues earned by entities through media preparation, biocatalyst optimization, mass production, downstream processing, and purification. The market value includes the value of related goods sold by the service provider or included within the service offering. The bioprocess technology market also includes sales of process columns, dispersers or emulsifiers, screens or sieves, filters, fermenters or bioreactors, and process homogenizers which are used in bioprocess technology. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.